GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Epizyme Inc (NAS:EPZM) » Definitions » PE Ratio (TTM)

Epizyme (Epizyme) PE Ratio (TTM) : At Loss (As of Apr. 26, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Epizyme PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-26), Epizyme's share price is $1.47. Epizyme's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-1.72. Therefore, Epizyme's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Epizyme's PE Ratio (TTM) or its related term are showing as below:

EPZM' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



EPZM's PE Ratio (TTM) is not ranked
in the Biotechnology industry.
Industry Median: 26.82 vs EPZM: At Loss

Epizyme's Earnings per Share (Diluted) for the three months ended in Jun. 2022 was $-0.21. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-1.72.

As of today (2024-04-26), Epizyme's share price is $1.47. Epizyme's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2022 was $-1.72. Therefore, Epizyme's PE Ratio without NRI for today is At Loss.

Epizyme's EPS without NRI for the three months ended in Jun. 2022 was $-0.21. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2022 was $-1.72.

During the past 3 years, the average EPS without NRI Growth Rate was -12.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was -4.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was -14.10% per year.

During the past 11 years, Epizyme's highest 3-Year average EPS without NRI Growth Rate was 51.50% per year. The lowest was -380.10% per year. And the median was -9.30% per year.

Epizyme's EPS (Basic) for the three months ended in Jun. 2022 was $-0.21. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2022 was $-1.72.


Epizyme PE Ratio (TTM) Historical Data

The historical data trend for Epizyme's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epizyme PE Ratio (TTM) Chart

Epizyme Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Epizyme Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Epizyme's PE Ratio (TTM)

For the Biotechnology subindustry, Epizyme's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epizyme's PE Ratio (TTM) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Epizyme's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Epizyme's PE Ratio (TTM) falls into.



Epizyme PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Epizyme's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=1.47/-1.720
=At Loss

Epizyme's Share Price of today is $1.47.
Epizyme's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.72.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Epizyme  (NAS:EPZM) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Epizyme PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Epizyme's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Epizyme (Epizyme) Business Description

Traded in Other Exchanges
N/A
Address
400 Technology Square, 4th Floor, Cambridge, MA, USA, 02139
Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing, and commercializing novel epigenetic medicines. Its product candidates include one approved product, TAZVERIK (tazemetostat), an inhibitor of the EZH2. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias and PRMT5 inhibitor.
Executives
Jeffery Kutok officer: Chief Scientific Officer 784 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Jerald Korn officer: Chief Operating Officer 128 GORDON RD, NEWTON MA 02468
Joseph Beaulieu officer: Corporate Controller C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Shefali Agarwal officer: Chief Medical Officer C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Royalty Pharma Investments 2019 Icav director, 10 percent owner C/O RP MANAGEMENT, LLC 100 E. 59TH ST., 33RD FLOOR NEW YORK NY 10022
Pablo G. Legorreta director 110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022
Carol Stuckley director C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Roy A Beveridge, director 500 W MAIN ST, LOUISVILLE KY 40202
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Robert B Bazemore director, officer: President & CEO 33 HAYDEN AVE, LEXINGTON MA 02421
Matthew Ros officer: Chief Operating Officer C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paolo Tombesi officer: Chief Financial Officer 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Victoria Vakiener officer: Chief Commercial Officer C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Carl Goldfischer director 161 WEST 61ST STREET, NEW YORK NY 10022
Rp Management, Llc director 110 EAST 59TH STREET SUITE 3300 NEW YORK NY 10022

Epizyme (Epizyme) Headlines

From GuruFocus

Palo Alto Investors LP Buys 2, Sells 3 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 11-15-2022

SHAREHOLDER ALERT: Weiss Law Investigates Epizyme, Inc.

By PRNewswire PRNewswire 07-07-2022